三生国健：707项目于2025年4月正式被国家药品监督管理局纳入突破性治疗品种

Group 1 - The core point of the article is that Sanofi's 707 project has been officially included as a breakthrough therapy by the National Medical Products Administration, targeting first-line treatment for PD-L1 positive locally advanced or metastatic non-small cell lung cancer [1] Group 2 - The 707 project is expected to be recognized as a significant advancement in cancer treatment by April 2025 [1] - The indication for the 707 project focuses on a specific patient population, which may enhance its market potential [1] - The inclusion in the breakthrough therapy category may expedite the development and approval process for the 707 project [1]